Navigation Links
Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Date:12/11/2012

r all development of ISIS-STAT3Rx other than the conduct of the ongoing clinical trial, which Isis will complete. Isis is eligible to receive further milestone payments subject to achieving certain predefined clinical success criteria for the ISIS-STAT3Rx program and pre-clinical milestones for the other programs. Isis is also eligible to receive downstream development and approval milestone payments, license fees for research program targets as well as royalties on sales from products that are successfully commercialized.

Isis will hold a conference call and live audio webcast today, December 11, 2012 at 8:30 am ET to provide detailed information on its new strategic alliance with AstraZeneca. Interested parties may listen to the call by dialing 866-713-8567and refer to passcode "ISIS 2012," or access the webcast at www.isispharm.com

ABOUT ISIS-STAT3Rx
ISIS-STAT3Rx is the first drug in Isis' pipeline that incorporates Isis' Generation 2.5 chemistry, which was developed to increase potency of antisense drugs thereby creating opportunities for drugs like ISIS-STAT3Rx to be more effective in addressing targets in a broader range of tissues, including tumors. ISIS-STAT3Rx is designed to inhibit the production of signal transducer and activator of transcription 3 (STAT3), a protein critical for tumor growth and survival. Because STAT3 is overexpressed in numerous types of cancers, ISIS-STAT3Rx has the potential to be broadly useful for both solid and hematological tumors. Isis recently reported encouraging data from its ongoing Phase 1 study showing that ISIS-STAT3Rx had an acceptable safety profile and treatment with ISIS-STAT3Rx resulted in clear responses in a number of patients with advanced cancer who were refractory to multiple prior chemotherapy treatments. The indication of activity so early in devel
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
2. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
3. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
5. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
6. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
7. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
8. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
9. Salix Pharmaceuticals Donates $500,000 To ASGEs IT&T Capital Campaign To Build A New State-of-the-Art GI Training Center
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Double-digit Growth Rate of the Pharmaceuticals Industry in Asia Pacific Boosts the API Market, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015  Imprimis Pharmaceuticals, ... focused on the development and commercialization of proprietary ... will ring The Nasdaq stock market closing bell ... the growing success of its Go Dropless™ campaign ... million cataract procedures are performed annually in the ...
(Date:7/1/2015)... July 1, 2015 Qiming Venture Partners, today ... Managing Partner effective immediately. William has been ... and participated in many Qiming healthcare deals, and assisted ... Chinese market. Qiming, s success in healthcare is not ... distinguished himself with his outstanding advocacy and service mentality ...
(Date:7/1/2015)... Md. , July 1, 2015 ExeGi ... biotherapeutics and probiotic treatments, announced today that it has ... Natural and Non-prescription Health Products Directorate (NNHPD) to sell ... Visbiome was developed by Professor Claudio De ... of extensive clinical investigation. Professor De Simone recently signed ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4Qiming Announces the Promotion of William Hu to Managing Partner 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
... Feb. 10, 2011 Renaissance Surgical Arts at Newport Harbor ... in the Western United States to offer intraoperative radiotherapy (IORT) ... the TARGIT-A multicenter human clinical trial that demonstrated IORT to ... early breast cancer. IORT has the potential ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... Financial Officer. Mr. Hoffman, who has accepted a new position in ... until the reporting of the company,s year-end results and the filing ... "We thank Robert for his many years of valuable ...
Cached Medicine Technology:Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 3Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer 2Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer 3
(Date:7/1/2015)... , ... July 01, 2015 , ... Convoy of ... community celebration in the Twin Cities on Saturday, August 1, at Spring Lake Park ... community will provide more than $1 million worth of goods and services including free ...
(Date:7/1/2015)... Louisville, KY (PRWEB) , ... July 01, 2015 ... ... Health Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying ... The paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . ...
(Date:7/1/2015)... Columbus, OH (PRWEB) , ... July 01, 2015 , ... ... pleased to announce Dr. Leslie King has been named Dean of the ... role as Dean, Dr. King will promote and support the vision and mission of ...
(Date:7/1/2015)... Luis Obispo, CA (PRWEB) , ... July 01, ... ... non-surgical bunion treatment, announces their big summer sale. Customers purchasing two or ... with promo code "Summer15". , Bunion Bootie temporarily corrects misaligned toes ...
(Date:7/1/2015)... ... ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively to ... for Capital Health in Pennington, N.J. One of the top ... more than 1,000 healthcare executives into organizations. , Capital Health is a two-hospital ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... A team of French surgeons took off on a specially ... attempt the first-ever operation // carried out in weightless ... ,The Airbus A300 is equipped with a special surgical module, ... future surgery carried out in the gravity-free conditions of outer ...
... of patented drugs will play host to a new entrant ... recent communique // by the Director of patent policy in ... arm for the multitude of generic drug manufacturers, who can ... to developing nations. ,Biolyse Pharma Corp., ...
... in the U.S. uncovered the secrets of the deadly Spanish flu ... across the world.// ,The pandemic took lives of ... severity of the virus was not understood then. ,Dr John Kash, ... a research by infecting mice with a reconstructed form of the ...
... Thiruvananthapuram: The Health Department has announced that it ... both prevention as well as // control measures, ... districts in Kerala, Thiruvananthapuram, Alappuzha, Ernakulum and Kozhikode ... of a slackened response by the Health watch ...
... a division that deals with the reconstruction of the ... the occurrence of birth defects like cleft palate. Since ... required. This will not only ensure a smooth operation, ... their face will look like in future., ,In ...
... cornea cells that may also explain how it evades the ... University of Illinois at Chicago College of Medicine. ... Journal of Cell Biology. ,Both strains of the ... on the mouth, and HSV-2, genital herpes -- can infect ...
Cached Medicine News:Health News:Spanish flu virus – secrets uncovere 2Health News:Mathematics And Beauty? You Bet! 2Health News:Herpes Infects Cornea, Evades Immune Cells 2
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... handheld oximeter has been converted to the ... now compatible with the entire line of ... Sensor and SoftCare Nonadhesive Sensors. The redesigned ... Nellcor's latest advanced signal processing technology, which ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: